Health Care/Hospital

First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery

MELBOURNE, Australia, Oct. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix's first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentu...

2024-10-04 04:00 2850

IBC launches RadSep, Inc.: Best-in-class, highly selective separations using Molecular Recognition Technology™ (MRT™) for production of critical radioisotopes essential to cancer therapies

* Best-in-class, highly selective separations technology for the radiopharmaceuticals industry * Exhibitor at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany 20-23 October 2024 at Booth S14 (Exhibition Hall 3) * Over 36 years of experience with first generatio...

2024-10-03 22:15 1730

WELLlife COVID-19/Influenza A&B Home Test on Sale for Amazon Prime Day

Standfirst: Welllife, a Flu home test in addition to COVID-19 BOLINGBROOK, Ill., Oct. 3, 2024 /PRNewswire/ -- WELLlife, a leading innovator in medical diagnostic and testing solutions, is increasing accessibility to respiratory illness testing this flu season. The WELLlife COVID-19/Influenza A&B...

2024-10-03 21:00 1175

The Exosome Production Method Patent by Panacell Biotech Registered as Original Technology

SEOUL, South Korea, Oct. 3, 2024 /PRNewswire/ -- Panacell Biotech Co., Ltd. (Panacell Biotech) announced that the patent related to their exosome manufacturing method filed last year was registered as a core technology in the patent registry onAugust 7, 2024, following the Patent Act. Panacell B...

2024-10-03 20:00 1694

Veritas Genetic participates in a groundbreaking study highlighting the importance of polygenic risk scores in the clinical management of breast cancer patients

* The study, conducted in collaboration with the Department of Biomedicine and Prevention at the University of Rome Tor Vergata and Tor Vergata University Hospital, underscores the relevance of polygenic risk scores (PRS) in risk stratification for patients with a genetic predisposition to brea...

2024-10-03 14:00 1735

CNN's 'Tomorrow Transformed' explores how the future of healthcare is connecting lives

HONG KONG, Oct. 3, 2024 /PRNewswire/ -- Since the dawn of healthcare, technology has been drastically improving medical systems and services to help us live longer and better lives. In this special half-hour episode of'Tomorrow Transformed', connections, partnerships, and collaborations in the wo...

2024-10-03 12:16 2281

Millennium Hotels and Resorts Pledges Solidarity for Breast Cancer Awareness Month

The global hospitality brand announces a collaborative event with breast cancer advocate and survivorJill Alphonso and sound healing expert Michele Chong of The Sirius Sound, alongside pink-themed F&B offerings. SINGAPORE, Oct. 2, 2024 /PRNewswire/ -- Millennium Hotels and Resorts (MHR) announce...

2024-10-03 11:41 2538

A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore

Organizations Plan to Jointly Advance Breakthrough Solutions in Human Health and Sustainability, Drive Research Collaboration, Entrepreneurship and Accelerate Talent Development SINGAPORE, Oct. 3, 2024 /PRNewswire/ -- The Agency for Science, Technology and Research (A*STAR),Singapore's lead publ...

2024-10-03 09:00 1924

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

-  Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV HYDERABAD, India, Oct. 2, 2024 /PRNewswire/ -- Hetero, India's leading pharmaceutical comp...

2024-10-02 22:53 2508

South Korea's SK bioscience Completes Acquisition of Germany's CDMO IDT Biologika

* SK bioscience completed the acquisition of German CDMO company IDT Biologika with over a century of history that enables immediate expansion in revenue and infrastructure. * The company aims to double sales of IDT Biologika by 2028 through new business projects and operational efficiency. ...

2024-10-02 20:00 1971

Zepp Regains Compliance with NYSE Minimum Price Continued Listing Criterion

MILPITAS, Calif., Oct. 2, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange ("NYSE") datedOctober 2, 2024 (the "Octobe...

2024-10-02 19:00 4002

Australia takes centre stage as a cure for Rett Syndrome draws closer

GOLD COAST, Australia, Oct. 2, 2024 /PRNewswire/ -- Australian researcher Associate ProfessorWendy Gold, a world leader in Rett Syndrome research from the University of Sydney, joins international colleagues and Rett families on theGold Coast today to present the l...

2024-10-02 05:48 1813

Baird Medical and ExcelFin Acquisition Corp Complete Business Combination

NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina (which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clear...

2024-10-02 05:37 3711

Astrix Accelerates Global Expansion with Enhanced Presence in Europe

Expanded European presence aims to meet increasing global demand from the life science industry. RED BANK, N.J., Oct. 1, 2024 /PRNewswire/ -- Astrix, the leader in delivering innovative strategies and solutions to the life science community through its market-leading strategic consulting and tec...

2024-10-01 21:16 1310

PeptiGrowth Inc. is Launching a Novel Synthetic FGF2 Alternative Peptide (FGFR1c Agonist)

TOKYO, Oct. 1, 2024 /PRNewswire/ -- PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo; President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called "FGF2 alternative peptide (FGFR1c agonist)", which has equivalent function to recombinant FGF2 (Fibroblast Growth Factor 2, ...

2024-10-01 21:00 1444

Precision Medicine Group Welcomes Margaret Keegan as CEO

-- Founding CEO Mark Clein named Executive Chairman; Mr. Clein and co-founder Ethan Leder to continue as Board Directors -- BETHESDA, Md., Oct. 1, 2024 /PRNewswire/ -- Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, to...

2024-10-01 20:49 1346

OPTEL and Worximity Join Forces to Boost Line Performance with Real-Time OEE Solutions

QUÉBEC CITY, Oct. 1, 2024 /PRNewswire/ -- OPTEL, a global leader in traceability and vision systems, and Worximity, a leading provider of OEE and real-time production monitoring, are partnering to help manufacturers boost operational efficiency.

2024-10-01 19:00 1081

Witsbb's Nutrient Origin Exploration Garners Over 11 Million Online Likes

SYDNEY, Oct. 1, 2024 /PRNewswire/ -- "Australia, here we come!" Recently, well-known Chinese bloggers @RainbowCouple traveled fromChina to Australia to embark on a nutrition traceability journey spanning 10,000 kilometers. They visited the headquarters of Witsbb, and their product origin live str...

2024-10-01 18:57 1905

Responding to spine surgeons' educational needs, AO Spine rolls out new competency-based curriculum courses in 2025

DAVOS, Switzerland, Oct. 1, 2024 /PRNewswire/ -- With a 20-plus-year legacy as the world's premier education provider in spine surgery, AO Spine —a clinical division of the AO —continues to revolutionize surgeon education with it...

2024-10-01 18:00 1450

Frost & Sullivan co-published Recombinant Type III Triple-Helix Collagen Whitepaper with Everon Healthcare

SHANGHAI, Oct. 1, 2024 /PRNewswire/ -- Frost & Sullivan and Everon Healthcare have conducted extensive investigation across the recombinant collagen Industry and co-published the "Recombinant Type III Triple-Helix Collagen Whitepaper" on Sep. 29th, 2024, which aims to analyze the latest research a...

2024-10-01 17:28 1843
1 ... 25262728293031 ... 847